- Vaccine Name: NY-ESO-1/PRAME/MAGE-A3/WT-1 Peptide Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Subunit vaccine
- Status: Clinical trial
- Host Species for Licensed Use: None
- Antigen: cancer testis antigens (NY-ESO-1, PRAME, MAGE-A3, and WT-1) (NCT02750995; NCIT_C127125)
- Immunization Route: Other
- Description: This is a peptide-based cancer vaccine comprised of synthetic peptides derived from the cancer-testis antigen NY-ESO-1, preferentially expressed antigen in melanoma (PRAME), human melanoma antigen A3 (MAGE-A3) and the human Wilms tumor protein-1 (WT-1), with potential immunostimulating and antineoplastic activities. NY-ESO-1/PRAME/MAGE-A3/WT-1 peptide vaccine may stimulate the immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing NY-ESO-1, PRAME, MAGE-A3 and WT-1, resulting in tumor cell lysis. (NCIT_C127125) As proteins are degraded in cells, peptides are presented on the surface of these cells as a complex with tissue type molecules (HLA molecules). T-cells may then recognize the peptide-HLA complexes, via its T-cell receptor, potentially resulting in tumor-cell killing, if sufficient priming takes place. Cancer testis antigens (CTA's) are known to be immunogenic and are only expressed at immunoprivileged sites, thus out of reach of immune responses, and on cancer cells, making them ideal targets for therapeutic cancer vaccination. The CTA's chosen were NY-ESO-1, MAGE-A3 and PRAME. WT-1 is additionally included as this protein has proven to be an important antigen in hematological malignancies. It is combined with azacitidine for treatment of patients with high-risk myelodysplastic syndrome or acute myeloid leukemia. (NCT02750995)
|
